Research institution
Mario Negri Institute for Pharmacological Research Clinical Trials
Studies where Mario Negri Institute for Pharmacological Research is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 34Glomerulopathy, C3G
Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on Podocytes in Patients With C3G and Primary IC-MPGN
This is a prospective, multicenter, non-interventional, observational pharmacological real-world study to characterize longitudinal changes in ex vivo biomarkers of complement activation in patients with C3G and primary IC-MPGN…
- Conditions
- Glomerulopathy, C3G, Membranoproliferative Glomerulonephritis (MPGN)
- Trial name
- COMPASS (NCT07904338)
- Testing
- Blood sample
- Where
- Italy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Breast Cancer, Interstitial Lung Disease (ILD)
Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan
Trastuzumab deruxtecan (T-DXd) has recently received approval as an antibody-drug conjugate for treating patients with metastatic breast cancer (BC) who have HER-2 protein expression as determined by immunohistochemistry…
- Trial name
- MARGARET (NCT07828054)
- Testing
- Dexamethasone, antiemetic premedication, T-DXd
- Volunteers
- 244 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Brain Injuries, Acute
Severe Acquired Brain Injuries: Prognostic Factors and Quality of Care
The main purpose of this project is to identify the medium-term prognostic factors for patients with Severe Acquired Brain Injuries and evaluate their impact.
- Trial name
- NCT04905264
- Where
- 27 sites in Italy
- Volunteers
- 2,500 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Cardiovascular (CV) Risk, Inflammation
RESOLving INflammation Through Diet for Health (RESOLVIN)
Hyperlipidemia is the main driver of atherosclerotic cardiovascular disease (ASCVD), both through direct effects and as trigger of the chronic inflammation behind a cardiovascular health-to-disease transition.
- Conditions
- Cardiovascular (CV) Risk, Inflammation, Omega 3
- Trial name
- RESOLving (NCT07331103)
- Testing
- Fish Oil, Camelina oil, Vitamin E
- Where
- 9 sites in Italy
- Volunteers
- 324 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Emergency Medicine
Propensity to Hospitalize Patients From the ED in European Centers.
The peer-to-peer comparison means center-to-center comparison, which requires adjusting for possible differences among centers to be fair and convincing.
- Trial name
- eCREAM-UC1 (NCT06354764)
- Testing
- no intervention
- Where
- 2 sites in Italy
- Volunteers
- 162,000 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Emergency Medicine
Development of a Multipurpose Dashboard to Monitor the Situation of Emergency Departments
An emergency department (ED) is a healthcare service that provides the first clinical assessment and treatment to patients with various acute conditions.
- Trial name
- eCREAM-UC2 (NCT06372379)
- Testing
- no intervention
- Where
- 2 sites in Italy
- Volunteers
- 162,000 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Emergency Departments
Emergency and Urgent Care Indicators in Piedmont
The Emergency Department represents the main entry point to the hospital and a key setting for the management of urgent healthcare needs in the population.
- Trial name
- PRIME (NCT07606209)
- Where
- Italy
- Volunteers
- 650,000 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Emergency Departments
Mild TBI in the Emergency Department
Mild TBI is one of the main causes of admission to the Emergency Department (ED). Brain computed tomography (CT) is one of the most widely used diagnostic tools to assess the presence of intracranial lesions.
- Trial name
- NCT07021118
- Where
- 59 sites in Italy, Switzerland
- Volunteers
- 2,500 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Amyotrophic Lateral Sclerosis
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS).
- Trial name
- ALCALS (NCT06126315)
- Testing
- Acetyl-l-carnitine
- Where
- 19 sites in Australia, Italy
- Volunteers
- 246 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Ovarian Cancer
Implementation of New Models of Ovarian Carcinoma Resistant to Therapy
The project focuses on developing new experimental models of ovarian cancer that accurately reflect patients who do not respond to first-line platinum-based treatments and who are resistant to PARP inhibitors (PARPi).
- Trial name
- NCT07757711
- Testing
- Platinum drugs and PARPi
- Volunteers
- 50 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Completed, with results posted
All 6Epilepsies, Partial
Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)
There are no guidelines on the first maintenance daily dose of antiepileptic drugs (AEDs) in newly diagnosed, previously untreated epilepsy.
- Trial name
- STANDLOW (NCT03689114)
- Testing
- Low dose carbamazepine, Standard dose carbamazepine, Low dose levetiracetam
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Ovarian Neoplasms
Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib
This is a Phase II, randomized, multi-centre study aiming at comparing the efficacy of Olaparib and Cediranib vs. weekly Paclitaxel in terms of progression free survival (PFS) in platinum refractory or resistant recurrent ovarian…
- Trial name
- BAROCCO (NCT03314740)
- Testing
- Paclitaxel, Cediranib, Olaparib
- Where
- 6 sites in Italy
- Volunteers
- 123 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Amyotrophic Lateral Sclerosis
The Effect of RNS60 on ALS Biomarkers
Amyotrophic Lateral Sclerosis (ALS) is a rare lethal neurodegenerative disease involving inflammation. Riluzole, the only drug for ALS, improves median survival by 3 months. This prompts new treatments of ALS.
- Trial name
- RNS60 (NCT03456882)
- Testing
- RNS60
- Where
- 23 sites in United States, Italy
- Volunteers
- 147 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Breast Cancer
Decision-aid on Breast Cancer Screening
The present study aim to assess the effect of an interactive web decision aid on informed choice - measured via knowledge, attitudes and intentions concerning breast cancer screening - comparing the decision aid with a standard…
- Trial name
- NCT03097653
- Testing
- Decision-aid, Standard information
- Where
- 7 sites in Italy
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Second Hand Tobacco Smoke
The TackSHS Survey: a Pan-European Study on SHS
Within the TackSHS project (H2020 project grant agreement No 681040), we will conduct a European cross-sectional study, aiming at i) estimating prevalence and investigating determinants of smoking, e-cigarette use and exposure to…
- Trial name
- NCT02928536
- Testing
- no intervention
- Where
- Italy
- Volunteers
- 11,902 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research